コンテンツへスキップ
Merck
すべての画像(1)

主要文書

5.05477

Sigma-Aldrich

MLN4924

≥98% (HPLC), solid, NAE inhibitor, Calbiochem®

別名:

NAE Inhibitor, MLN4924, ((1S,2S,4R)-4-(4-((1S)-2,3-Dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate, NEDD8-Activating Enzyme Inhibitor, NEDD8-Activating Enzyme Inhibitor, ((1S,2S,4R)-4-(4-((1S)-2,3-Dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C21H25N5O4S
CAS番号:
分子量:
443.52
MDL番号:
UNSPSCコード:
12352200
NACRES:
NA.77
Pricing and Inventory is not available. Please check the Merck website for more information.

製品名

NAE Inhibitor, MLN4924,

アッセイ

≥98% (HPLC)

品質水準

フォーム

solid

有効性

4.7 nM IC50

メーカー/製品名

Calbiochem®

保管条件

OK to freeze
protect from light

light beige

溶解性

DMSO: 100 mg/mL

保管温度

2-8°C

詳細

MLN4924 is a specific small molecule NEDD8-activating enzyme (NAE) inhibitor. Neddylation involves adding Nedd8, an ubiquitin-like molecule, to target proteins. This post-translational protein modification is associated with cancer development. MLN4924 is known to induce dose-dependent anti-proliferation, anti-migration, anti-invasion in ccRCC cells. MLN4924 is a cell-permeable AMP mimetic. The mechanism of action is found to target the NEDD8-activating E1 enzyme NAE nucleotide-binding site and undergoes a NAE-catalyzed covalent NEDD8 adduct formation, the adduct in turn acts as a tight-binding, ATP-competitive NAE inhibitor (IC50 = 4.7 nM), exhibiting much reduced or little potency against UAE/UBA1, UBA6/UBE1L2, SAE, ATG7, adenosine receptors A1/A2A/A2B/A3, or a panel of 12 cellular kinases. Selectively reduces cellular Ubc12-NEDD8, but not Ubc9-SUMO or Ubc10-Ub, thioester formation (ICmax = 90 nM in HCT-116 cultures in 24 h), resulting in cullin-RING ligases substrates elevation. Shown to inhibit the growth of various cancer cells both in cultures (IC50 from 50 nM to 1.03 µM) in vitro and in murine xenograft models (30 to 60 mg/kg via s.c.) in vivo via apoptosis induction.

アプリケーション

MLN4924 has been used as a neddylation inhibitor:

  • to treat cell lines stably expressing a GaLV/MLV chimera construct in order to study its effects on viral transduction and infectivity[1]
  • to study its effects on the accumulation of LCMT1, suggesting a potential role in regulating LCMT1 stability and degradation in LNCaP cells[2]
  • to study UBX-390-mediated degradation of androgen receptor (AR) via proteasomal action in a prostate cancer cell line[3]

生物化学的/生理学的作用

Cell permeable: yes
Primary Target
NEDD8-Activating Enzyme
Reversible: no

包装

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

再構成

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
Use only fresh DMSO for reconstitution.

その他情報

Milhollen, M.A., et al. 2010. Blood116, 1515.

Brownell, J.E., et al. 2010. Mol. Cell37, 102.

Soucy, T.A., et al. 2009. Nature458, 73.

法的情報

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

保管分類コード

11 - Combustible Solids

WGK

WGK 2

引火点(°F)

Not applicable

引火点(℃)

Not applicable


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

Shuai Tong et al.
Scientific reports, 7(1), 5599-5599 (2017-07-19)
Neddylation is a post-translational protein modification associated with cancer development. MLN4924 is a neddylation inhibitor currently under investigation in multiple phase I studies on various malignancies, and its clincal name is Pevonedistat. It has been documented that MLN4924 blocks Cullins
Soohyun Lee et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), e2400398-e2400398 (2024-07-03)
The androgen receptor (AR) is an attractive target for treating prostate cancer, considering its role in the development and progression of localized and metastatic prostate cancer. The high global mortality burden of prostate cancer, despite medical treatments such as androgen
Carolyn A Robinson et al.
Viruses, 14(4) (2022-04-24)
HIV-1 Vpu targets the host cell proteins CD4 and BST-2/Tetherin for degradation, ultimately resulting in enhanced virus spread and host immune evasion. The discovery and characterization of small molecules that antagonize Vpu would further elucidate the contribution of Vpu to
Reyaz Ur Rasool et al.
Nature communications, 14(1), 5253-5253 (2023-08-30)
Loss of the tumor suppressive activity of the protein phosphatase 2A (PP2A) is associated with cancer, but the underlying molecular mechanisms are unclear. PP2A holoenzyme comprises a heterodimeric core, a scaffolding A subunit and a catalytic C subunit, and one
Rizwan Saffie et al.
Cancer research, 80(12), 2498-2511 (2020-05-01)
Mature B-cell neoplasms are the fifth most common neoplasm. Due to significant heterogeneity at the clinical and genetic levels, current therapies for these cancers fail to provide long-term cures. The clinical success of proteasome inhibition for the treatment of multiple

関連コンテンツ

Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.

タンパク質の単離と特性解析におけるタンパク質分解を予防して、サンプル調製でタンパク質を保護するために、ニーズに応じてさまざまなプロテアーゼ阻害剤を選択しましょう。

質問

レビュー

評価値なし

アクティブなフィルタ

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)